Get the Stockscreener App
3.80
4.28%
-0.17
Quantum Biopharma Ltd stock is traded at $3.80, with a volume of 165.21K.
It is down -4.28% in the last 24 hours and down -39.39% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$3.97
Open:
$4.15
24h Volume:
165.21K
Relative Volume:
0.34
Market Cap:
$24.31M
Revenue:
-
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.46
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
-5.00%
1M Performance:
-39.39%
6M Performance:
-56.92%
1Y Performance:
-74.82%
1-Day Range:
$3.70
$4.15
1-Week Range:
$3.52
$4.22
52-Week Range:
$2.07
$19.12
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.80 | 24.31M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
Quantum BioPharma Ltd (QNTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quantum BioPharma Ltd (QNTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment - TradingView
Quantum BioPharma Advances Lucid-MS Therapy for Multiple Sclerosis After Positive Phase 1 Trial - citybuzz -
Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Ltd. Subordinate Voting Shares - The Canadian Securities Exchange (CSE)
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast - NewMediaWire
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - TipRanks
Quantum BioPharma Hires Stocks.news for Investor Relations Services in $250,000 Deal - citybuzz -
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate and Alcohol Metabolism Product - citybuzz -
Quantum BioPharma Hit by FDA Clinical Hold on Lead MS Drug as Director Resigns - TipRanks
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - citybuzz -
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma hires IR Agency for investor relations By Investing.com - Investing.com Australia
Quantum BioPharma Hires Stocks.news IR Agency to Boost Market Visibility - TipRanks
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns - The Manila Times
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead ... - Caledonian Record
Quantum BioPharma (QNTM) hires Stocks.news in US$250K investor relations push - Stock Titan
Quantum BioPharma Engages Stocks.news For Investor - GlobeNewswire
QNTM Technical Analysis & Stock Price Forecast - Intellectia AI
Quantum BioPharma Ltd. Provides Update on FDA Clinical Hold for Lucid-MS Drug Candidate - Quiver Quantitative
Quantum BioPharma Provides Corporate Update - Toronto Star
QNTM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Quantum Biopharma Ltd. Q4 2025 Earnings: Wider Loss as Pre-Revenue Biotech Navigates Pipeline Progress - thelegaladvocate.com
Quantum BioPharma Advances MS Therapy, Diversifies Pipeline with Wellness Products - citybuzz -
Quantum BioPharma Momentum Surges Amid MS Resarch UpdateQuantum BioPharma (NASDAQ:QNTM) - Benzinga
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Narrowing Losses Amidst No Revenue DisclosureEPS Surprise History - thelegaladvocate.com
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Net Loss Deepens as Pre-Revenue Stock Sheds 23.7%Annual Earnings Summary - lwvtexas.org
QNTM Q4 2025 Earnings: Loss Per Share Reported, Shares Surge on Biotech ProgressTrough Earnings Signal - The Legal Advocate
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Biotech Reports Wider Loss Amid Strategic Progress, Stock Jumps 18%Certified Trade Ideas - Newser
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Pre-Revenue Biotech Reports Narrowed Loss, Shares RallyEstimate Accuracy - newsline.com
Quantum BioPharma Reaches Halfway Point in Patient Enrollment in Imaging Study With MGH - Moomoo
Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study - NewMediaWire
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital - Sahm
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study - TipRanks
Quantum BioPharma (QNTM) Achieves Key Enrollment Milestone in MS Study - GuruFocus
Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) - Yahoo Finance
Quantum BioPharma reaches midpoint in MGH MS imaging study - grafa.com
Quantum BioPharma stock surges on MS imaging study progress By Investing.com - Investing.com Australia
Quantum BioPharma stock surges on MS imaging study progress - Investing.com
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):